Editas Medicine, Inc. Common Stock
Symbol: EDIT (NASDAQ)
3.53
▲ (1.84%) 0.064
Company Description:
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Key Stats
- Today's Open: $3.46
- Today's High: $3.705
- Today's Low: $3.416
- Today's Volume: 3.54M
- Yesterday Close: $3.47
- Yesterday High: $3.62
- Yesterday Low: $3.36
- Yesterday Volume: 2.59M
- Last Min Volume: 350
- Last Min High: $3.534
- Last Min Low: $3.518
- Last Min VWAP: $3.518
Company Profile
- Name: Editas Medicine, Inc. Common Stock
- Website: https://www.editasmedicine.com
- Listed Date: 2016-02-03
- Location: CAMBRIDGE, MA
- Market Status: Active
- CIK Number: 0001650664
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $312.02M
- Round Lot: 100
- Outstanding Shares: 89.92M
- Asset Type: CS
RECENT FILINGS FOR EDIT
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-04 | 4 | View |
| 2025-09-04 | 4 | View |
| 2025-09-04 | 4 | View |
| 2025-09-02 | 8-K | View |
| 2025-08-29 | 144 | View |
| 2025-08-29 | 144 | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-08-08 | 4 | View |
| 2025-08-04 | 4 | View |
| 2025-07-30 | 144 | View |
| 2025-06-12 | 8-K | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-10 | 4 | View |
| 2025-06-04 | 4 | View |
| 2025-06-04 | 4 | View |
| 2025-06-04 | 4 | View |
Latest News on EDIT